Validation study to explore potential outcome parameters for a study with anti-IL-13 in allergic syndrome/asthma.

1. Male or female subjects;

2. 18-50 years of age with atopic rhinitis.

1. Current smokers (<6 months stopped) or ex-smokers (>10 packyears);

2. Any clinically significant deviation from normal in either the general physical examination or laboratory parameters as evaluated by the investigator at Occasion 1;

3. Not able to stop maintenance therapy.
The following medicactions should be stopped before and during the study:

a. topical or systemic anti-inflammatory therapy with anti-IgE (>6 months);

b. corticosteroids inhaled or nasal sprays (>6 weeks);

c. oral corticosteroids >8 weeks;

d. LTRAs >4 weeks;

e. cromones >2 wk;

f. anticholinergics >1 wk;

g. long-acting oral antihistamines >7 days;

h. short-acting oral antihistamines > 2 days;

i. theophylline >3 days.

j. No other nasal sprays (other than ICS) cromoglycate >2 wk;

k. nasal antihistamines >2 days;

l. xylomethazolin and NaCl 0.9% >1 day;

4. Use of topical corticosteroid containing cr¨¨mes on maintenance basis on the site of investigation (volar side of underarms, or elbows);

5. History of serious food or medication allergy or anaphylaxis;

6. History of alcohol or drug abuse;

7. Desensibilization therapy in the past;

8. Vaccinations in the past 1 month;

9. Viral respiratory tract infections within 3 weeks;

10. Nasal polyps;

11. Nasal surgery in the past 3 months;

12. Not able to collaborate in the study;

13. Treatment with any investigational drug for at least 3 months prior to this study or ¡Ý3 clinical trial participations in the last year;

14. Positive serology to hepatitis B or C or human immunodeficiency virus (HIV);

15. Blood donation of more than 500 ml during the previous 3 months (men) or 4 months (women), according to Sanquin guidelines.